Comparison of Acute Kidney Injury Risks Between Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: A Propensity Score-weighted Retrospective Observational Cohort Study
This retrospective cohort study utilizing propensity score weighting found that among patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants, edoxaban was associated with a significantly lower risk of acute kidney injury within one year compared to apixaban and rivaroxaban.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of people living with an irregular heartbeat known as atrial fibrillation, the risk of blood clots forming in the heart is a constant, silent threat. These clots can travel to the brain and cause a stroke, a devastating event that doctors work tirelessly to prevent. For decades, the standard defense has been a class of drugs called anticoagulants, often referred to as blood thinners. While these medications are life-saving, they carry their own set of risks. One of the most serious is a condition where the kidneys suddenly stop working properly, a state known as acute kidney injury. This can happen when the medication causes bleeding inside the kidney's filtering tubes, leading to inflammation and damage. While doctors have long known that older blood thinners could cause this problem, the safety profile of newer, more modern drugs in this category has been less clear. Specifically, researchers have wondered if all the newer options are equally gentle on the kidneys, or if some might be safer than others.
A team of researchers at Sapporo Medical University Hospital in Japan set out to answer this question by looking at the real-world experiences of nearly five hundred patients. They focused on three specific modern blood thinners: edoxaban, apixaban, and rivaroxaban. These drugs belong to a group called direct oral anticoagulants, which are widely prescribed because they are generally easier to manage than older alternatives. The scientists reviewed the medical records of patients who started taking one of these three drugs between 2015 and 2023. Their goal was simple: to see which of the three medications was most likely to lead to acute kidney injury within the first year of treatment. To ensure a fair comparison, the researchers used a statistical method to balance the groups, making sure that differences in age, weight, or other health conditions did not skew the results.
The study revealed a clear difference in how these drugs affected the kidneys. Among the patients taking edoxaban, about 11 percent developed acute kidney injury within a year. In contrast, the rates were significantly higher for the other two drugs. Nearly 23 percent of patients on apixaban and a quarter of those on rivaroxaban experienced kidney injury during the same period. The data showed that patients taking apixaban were more than twice as likely to develop kidney injury compared to those on edoxaban, while those on rivaroxaban faced nearly three times the risk. These findings held true even when the researchers looked specifically at patients who already had some degree of kidney weakness before starting the medication. In that group, the risk associated with rivaroxaban was particularly high, while the risk for apixaban was also elevated, though the difference was less pronounced than with rivaroxaban.
The researchers noted that these results were surprising because the drugs are all designed to work in very similar ways, blocking the same enzyme in the blood clotting process. They considered whether the higher risk might simply be due to the drugs building up in the body because the kidneys could not clear them fast enough, but the numbers did not line up with that theory. Instead, the team suggested that the differences might stem from how each drug interacts with the body's tissues beyond just its blood-thinning effect, or perhaps from how often bleeding occurs in the kidneys with each specific medication. While the study was limited to a single hospital and a relatively small number of patients, the consistency of the results across different types of patients gave the findings weight. The authors concluded that among the three options, edoxaban appeared to be the safest choice for protecting the kidneys, a crucial piece of information for doctors who must weigh the benefits of stroke prevention against the potential for organ damage.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.